Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance

Vaccine. 1992;10(3):142-4. doi: 10.1016/0264-410x(92)90002-2.


Prolonged unblinded passive surveillance of the trial cohort from the Swedish 1986-87 pertussis vaccine efficacy trial indicates that a two-component vaccine, containing pertussis toxoid and filamentous haemagglutinin, provided better long-term protection against pertussis than a monocomponent pertussis toxoid vaccine. The relative risk (RR) for culture-confirmed pertussis was 1.5 (95% confidence interval (CI) 1.0-2.4), and RR for pertussis according to parents' diagnoses was also 1.5 (95% CI 1.1-2.1), for the monocomponent vaccine compared with the two-component vaccine.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Female
  • Humans
  • Incidence
  • Infant
  • Male
  • Pertussis Vaccine / therapeutic use*
  • Time Factors
  • Whooping Cough / epidemiology
  • Whooping Cough / prevention & control*


  • Pertussis Vaccine